SOM Biotech announces the completion of recruitment in the Phase IIb study of the treatment of chorea in Huntington’s disease patients with SOM3355

por Som Biotech

8 days ago
SOM3355, Huntington

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Pha...

SOM Biotech presents positive Phase 2a data with SOM3355 at the 34thECNP Congress 2021

por Som Biotech

3 years ago
SOM Biotech, computational technology, Huntingdon’s Disease

SOM Biotech today announces it will be presenting positive Phase 2a data with SOM3355, an oral vesicular monoamine transporter 2 (VMAT2) inhibitor for the symptomatic treatment of chorea movements ass...

SOM Biotech to participate at the BIO-Equity Europe 2021

por Som Biotech

3 years ago
SOM Biotech, BIO-Equity Europe 2021

SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17th – 19th, which will take place digitally.

SOM Biotech at Chiba Healthcare Business Forum 2021

por Som Biotech

3 years ago
pharmaceutical, drug discovery, platform, life science, Chiba Healthcare Business Forum

SOM Biotech will attend the “Chiba Global Healthcare Business Forum 2021” on February 3rd – 4th, which will take place digitally due to the pandemic situation.

SOM Biotech at the BIO- Partnering JPM Virtual Event 2021

por Som Biotech

3 years ago
conference, biotechnology industry, BIO-Partnering

SOM Biotech announces its participation at the BIO-Partnering at JP Morgan Healthcare Conference 2021, being held virtually on January 11th – 15th.

La Vanguardia published a press release: 'The future of biotechnology: lower-cost treatments in a short period of time'

por Som Biotech

3 years ago
La Vanguardia, biotechnology, Artificial Intelligence, rare diseases, Central Nervous System

SOM Biotech has designed a computational Artificial Intelligence-based method to analyze molecular structures and select the best option after performing more than 2.5 million comparisons in each p...

European Biotechnology: 'A pioneering real AI drug discovery technology'

por Som Biotech

3 years ago
drugs, covid-19, treatments, technologies, AI, SOMAI PRO

European Biotechnology Life Science and Industry Magazine published the article “A pioneering real AI drug discovery technology” describing the approach of SOM Biotech.

SOM Biotech keynote speaker at the Drug Discovery Innovation Programme Virtual Event 2020

por Som Biotech

3 years ago
Drug Discovery, Virtual Event, Biotechnology industry

SOM Biotech announces its participation at the Drug Discovery Innovation Programme event 2020, being held virtually on November 17th. The conference will be chaired by Kevin McAllister, PhD, MBA Chief...

SOM Biotech presents its drug candidate for the Chorea in Huntington Disease at the XIX Pharma – Biotech Cooperation conference

por Som Biotech

3 years ago
Huntington Disease, drug candidate, Farmaindustria

SOM Biotech presents its drug candidate SOM3355 for the Chorea in Huntington Disease at the XIX Pharma-Biotech Cooperation conference, November 12th 2020.

SOM Biotech identifica la Eravaciclina como tratamiento eficaz frente al SARS-CoV-2

por Som Biotech

4 years ago
Eravaciclina, fármaco, enfermedad respiratoria, SARS-CoV-2, SOMAIPRO, IDWeek 2020, inteligencia artificial

SOM Biotech, compañía biofarmacéutica especializada en el reposicionamiento de fármacos, anuncia que los resultados de los estudios in silico e in vitro realizados sobre el fármaco Eravaciclina d...

SOM Biotech has attended the virtual workshop on the World Duchenne Awareness Day 2020

por Som Biotech

4 years ago
Duchenne Parent Project, collaboration, treatments, R&D process, drug development

SOM Biotech has attended the virtual V Workshop “Duchenne and the Brain” organized by the Duchenne Parent Project Spain on September 7th, on the occasion of the World Duchenne Awareness Day 2020.

SOM Biotech obtiene fondos del CDTI para iniciar los ensayos clínicos con un fármaco para inhibir la replicación de la COVID-19

por Som Biotech

4 years ago
fondos, CDTI, fármaco, covid-19, Eravaciclina

SOM Biotech, compañía biofarmacéutica para el desarrollo y descubrimiento de fármacos, anuncia la obtención de una subvención de 340.000 euros otorgada por el CDTI (Centro para el Desarrollo Tec...